AMRX
Amneal Pharmaceuticals, Inc.
17.32
2 x 12.30
2 x 21.86
bid
ask
+
0.35
2.03%
09:52 AM
timesize
Ytd37.42%
1y106.87%
17.02
day range
17.33
7.67
52 week range
17.86
Open17.06Prev Close16.97Low17.02High17.33Mkt Cap5.53B
Vol47.47KAvg Vol1.86MEPS0.37P/E46.84Forward P/E15.11
Beta1.32Short Ratio4.27Inst. Own52.07%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0450-d Avg13.99200-d Avg12.681yr Est17.25

AMRX News

Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
benzinga.com
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness

FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after recei

benzinga.com
Zambon And Amneal's Hopledo Receives Positive CHMP Opinion For Parkinson's Disease, European Launch

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significan

Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations
globenewswire.com
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson's D

MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals tod

Why Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Term
zacks.com
Why Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

The Healthcare M&A Wave
forbes.com
The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc

benzinga.com
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose

https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-

Top 3 Health Care Stocks That May Collapse This Quarter
benzinga.com
Top 3 Health Care Stocks That May Collapse This Quarter

3 health care stocks flashing warning: CAH RSI 77.7, TGTX RSI 79.8, AMRX RSI 76.9; all overbought, b

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?
zacks.com
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a l

Is Amneal Pharmaceuticals Inc (AMRX) Overvalued After 4.4% Rally? GF Value Says Overvalued
gurufocus.com
Is Amneal Pharmaceuticals Inc (AMRX) Overvalued After 4.4% Rally? GF Value Says Overvalued

On June 10, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 4.4% today, bringing the current pri

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
gurufocus.com
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR New

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
prnewswire.com
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underse

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase
marketbeat.com
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase

Amneal Pharmaceuticals NASDAQ: AMRX Co-Founder, President and Co-Chief Executive Officer Chirag Pate

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conferen

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conferen

Amneal and Pfizer GLP-1 Deal: New Growth Lever?
zacks.com
Amneal and Pfizer GLP-1 Deal: New Growth Lever?

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to s

Is Amneal a Buy Before Rytary Generic Erosion?
zacks.com
Is Amneal a Buy Before Rytary Generic Erosion?

AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and hi

What's Driving Amneal's 2026 Growth Outlook?
zacks.com
What's Driving Amneal's 2026 Growth Outlook?

AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth fro

Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
zacks.com
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
zacks.com
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution

AMRX gains after FDA approval of ready-to-use romidepsin injection, with 180-day exclusivity and a p

benzinga.com
Amneal Pharmaceuticals Announces New Interim Results From Phase 4 Study Reinforcing Reported Benefit

Overall Interim Findings (Entire Study Population, 214Patients; Six-Week Analysis)All 214 patients w

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
globenewswire.com
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Re

BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“A

Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution
proactiveinvestors.com
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution

Amneal Pharmaceuticals (NASDAQ:AMRX) said on Thursday the US Food and Drug Administration has approv

Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution
proactiveinvestors.com
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution

Amneal Pharmaceuticals (NASDAQ:AMRX) said on Thursday the US Food and Drug Administration has approv

benzinga.com
Amneal Pharmaceuticals Romidepsin Injection Solution Receives FDA Approval

Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announc

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
globenewswire.com
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requ

Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?
zacks.com
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
globenewswire.com
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026

BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“A

benzinga.com
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $16

Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight

Earnings Scheduled For May 1, 2026
benzinga.com
Earnings Scheduled For May 1, 2026

Why Is Amneal Pharmaceuticals Stock Gaining Today?
benzinga.com
Why Is Amneal Pharmaceuticals Stock Gaining Today?

Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars pla

benzinga.com
Amneal Pharmaceuticals To Acquire Kashiv BioSciences For $375M In Cash, $375M In Shares Payable Upon

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a diversifie

benzinga.com
Amneal Pharma Presents New Interim Results From Ongoing Phase 4 ELEVATE-PD Study, At 2026 AAN

Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of C

benzinga.com
UBS Initiates Coverage On Amneal Pharmaceuticals with Buy Rating, Announces Price Target of $19

UBS analyst Ashwani Verma initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy r

benzinga.com
FDA Takes Step Forward on Testosterone Therapy for Men

https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

benzinga.com
Truist Securities Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $17

Truist Securities analyst Les Sulewski maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy

Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million
benzinga.com
Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million

Amneal beats fourth-quarter earnings and revenue estimates, driven by CREXONT sales, and guides up t

Earnings Scheduled For February 27, 2026
benzinga.com
Earnings Scheduled For February 27, 2026

Amneal Pharmaceuticals Q4 Earnings Summary & Key Takeaways
benzinga.com
Amneal Pharmaceuticals Q4 Earnings Summary & Key Takeaways

benzinga.com
Amneal Pharmaceuticals Sees FY2026 Adj EPS $0.93-$1.03 vs $0.94 Est; Sees Sales $3.050B-$3.150B vs $

Amneal Pharmaceuticals (NASDAQ:AMRX) is looking for FY2026 Adj EPS of $0.93-$1.03 vs $0.94 analyst e

benzinga.com
Amneal Pharmaceuticals Q4 Adj. EPS $0.21 Beats $0.18 Estimate, Sales $814.319M Beat $807.895M Estima

Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.21 per share which beat the a

Earnings Outlook For Amneal Pharmaceuticals
benzinga.com
Earnings Outlook For Amneal Pharmaceuticals

benzinga.com
If You Invested $100 In Amneal Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today

benzinga.com
Amneal Pharmaceuticals To Be Added To S&P SmallCap 600 Index, Effective Jan. 30

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announ

benzinga.com
Amneal Pharmaceuticals Affirms FY2025 Adj EPS Guidance of $0.75-$0.80 vs $0.80 Est; Affirms FY2025 S

Amneal Pharmaceuticals (NASDAQ:AMRX) affirms FY2025 Adj EPS guidance from $0.75-$0.80 to $0.75-$0.80

benzinga.com
KeifeRx Enters Into A Research Collaboration And Option Agreement With Amneal Pharmaceuticals To Sup

KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodege

benzinga.com
Amneal Pharmaceuticals Gets FDA's Approval For Biologics Licensing Applications For Boncresa, Oziltu

Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) and mAbxience

benzinga.com
Barclays Initiates Coverage On Amneal Pharmaceuticals with Overweight Rating, Announces Price Target

Barclays analyst Glen Santangelo initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with

benzinga.com
Amneal Pharmaceuticals Announced New Interim Results From Its Ongoing Phase 4 ELEVATE-PD Study, Pres

Interim data show substantial improvements in "Good On" time compared to other oral CD/LD th

benzinga.com
Amneal Pharmaceuticals Announces FDA's Approval For Albuterol Sulfate Inhalation Aerosol

Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (Nasdaq: AMRX) today announ

benzinga.com
Amneal Pharmaceuticals Announces U.S. FDA Approves Its Iohexol Injection

Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announc

benzinga.com
Piper Sandler Reiterates Overweight on Amneal Pharmaceuticals, Raises Price Target to $13

Piper Sandler analyst David Amsellem reiterates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overw